Foresite Capital Management IV’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,808,034
| Closed | -$19.2M | – | 6 |
|
|
2023
Q3 | $19.2M | Hold |
2,808,034
| – | – | 10.68% | 3 |
|
|
2023
Q2 | $29.1M | Hold |
2,808,034
| – | – | 14.32% | 4 |
|
|
2023
Q1 | $22.7M | Hold |
2,808,034
| – | – | 11.79% | 4 |
|
|
2022
Q4 | $44.2M | Hold |
2,808,034
| – | – | 18.89% | 2 |
|
|
2022
Q3 | $44.2M | Hold |
2,808,034
| – | – | 14.21% | 3 |
|
|
2022
Q2 | $39.2M | Sell |
2,808,034
-91,000
| -3% | -$1.27M | 10.56% | 4 |
|
|
2022
Q1 | $50M | Sell |
2,899,034
-500,000
| -15% | -$8.62M | 13.98% | 4 |
|
|
2021
Q4 | $49.4M | Hold |
3,399,034
| – | – | 10.17% | 3 |
|
|
2021
Q3 | $61.2M | Hold |
3,399,034
| – | – | 9.01% | 3 |
|
|
2021
Q2 | $59.7M | Hold |
3,399,034
| – | – | 8.07% | 4 |
|
|
2021
Q1 | $85.7M | Buy |
3,399,034
+2,447,650
| +257% | +$61.7M | 10.26% | 3 |
|
|
2020
Q4 | $6.16M | Buy |
951,384
+806,510
| +557% | +$5.22M | 0.67% | 12 |
|
|
2020
Q3 | $372K | Buy |
+144,874
| New | +$372K | 0.08% | 15 |
|
|
2019
Q1 | – | Sell |
-748,132
| Closed | -$5.53M | – | 17 |
|
|
2018
Q4 | $5.53M | Buy |
748,132
+218,581
| +41% | +$1.62M | 2.54% | 14 |
|
|
2018
Q3 | $7.69M | Hold |
529,551
| – | – | 2.52% | 13 |
|
|
2018
Q2 | $10.6M | Buy |
529,551
+100,000
| +23% | +$2M | 3.6% | 11 |
|
|
2018
Q1 | $7.53M | Buy |
429,551
+177,615
| +71% | +$3.11M | 3.12% | 11 |
|
|
2017
Q4 | $6.21M | Buy |
+251,936
| New | +$6.21M | 4.36% | 8 |
|